Bradykinin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  • Joseph Coulson University of Edinburgh
  • Réjean Couture Université de Montréal
  • Alexander Faussner Ludwig-Maximilians-Universität
  • Fernand Gobeil Jr Université de Sherbrooke
  • Fredrik Leeb-Lundberg Lunds Universitet
  • Francois Marceau Université Laval
  • Werner Muller-Esterl Johann Wolfgang Goethe-University
  • Doug Pettibone Merck Research Laboratories
  • Bruce Zuraw University of California San Diego


Bradykinin (or kinin) receptors (nomenclature as agreed by the NC-IUPHAR subcommittee on Bradykinin (kinin) Receptors [76]) are activated by the endogenous peptides bradykinin (BK), [des-Arg9]bradykinin, Lys-BK (kallidin), [des-Arg10]kallidin, [Phospho-Ser6]-Bradykinin, T-kinin (Ile-Ser-BK), [Hyp3]bradykinin and Lys-[Hyp3]-bradykinin. Variation in pharmacology and activity of B1 and B2 receptor antagonists at species orthologs has been documented. icatibant (Hoe140, Firazir) is approved in North America and Europe for the treatment of acute attacks of hereditary angioedema.
How to Cite
Coulson, J., Couture, R., Faussner, A., Gobeil Jr, F., Leeb-Lundberg, F., Marceau, F., Muller-Esterl, W., Pettibone, D. and Zuraw, B. (2019) “Bradykinin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database”, IUPHAR/BPS Guide to Pharmacology CITE, 2019(4). doi: 10.2218/gtopdb/F10/2019.4.